Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Peterson, Douglas E.; Boers–Doets, Christine B.; Bensadoun, René-Jean; Herrstedt, Jørn

doi:10.1093/annonc/mdv202

Cited by 204 publications

(170 citation statements)

References 40 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Gastritis was described in rare cases with the use of Imatinib, Sunitinib and Gefitinib. These toxicities were not included in the ESMO Guidelines on the management of oral and gastrointestinal mucosal injury (Peterson et al, 2015).…”

Section: Chemotherapy-induced Gastric Damagementioning

confidence: 99%

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

Numico

Fusco

Franco

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Chemotherapy-induced Gastric Damagementioning

confidence: 99%

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

Numico

Fusco

Franco

et al. 2017

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

“…Current management guidelines of oral mucosal injury focus on oral mucositis associated with chemotherapy or radiotherapy 8, 53, 54, 55. New guidelines specifically developed for the prevention and treatment of mIAS are needed.…”

Section: Preventing and Treating Mtor Inhibitor–associated Stomatitismentioning

confidence: 99%

“…The pathogenesis and clinical phenotype of oral mucositis caused by high‐dose chemotherapy or radiotherapy are well described in the literature 1, 2, 3, 4, 5, 6, 7, 8. In contrast, a unique manifestation of oral mucosal injury has been documented within the past 5 years in association with mammalian target of rapamycin (mTOR) inhibitors 8, 9, 10.…”

Section: Introductionmentioning

confidence: 99%

“…In contrast, a unique manifestation of oral mucosal injury has been documented within the past 5 years in association with mammalian target of rapamycin (mTOR) inhibitors 8, 9, 10. This latter toxicity has now emerged as one of the most common adverse events associated with targeted cancer therapies 11, 12, 13, 14, 15, 16, including in women being treated for invasive breast cancer 17, 18.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

et al. 2016

View full text Add to dashboard Cite

In recent years oral mucosal injury has been increasingly recognized as an important toxicity associated with mammalian target of rapamycin (mTOR) inhibitors, including in patients with breast cancer who are receiving everolimus. This review addresses the state‐of‐the‐science regarding mTOR inhibitor‐associated stomatitis (mIAS), and delineates its clinical characteristics and management. Given the clinically impactful pain associated with mIAS, this review also specifically highlights new research focusing on the study of the molecular basis of pain. The incidence of mIAS varies widely (2–78%). As reported across multiple mTOR inhibitor clinical trials, grade 3/4 toxicity occurs in up to 9% of patients. Managing mTOR‐associated oral lesions with topical oral, intralesional, and/or systemic steroids can be beneficial, in contrast to the lack of evidence supporting steroid treatment of oral mucositis caused by high‐dose chemotherapy or radiation. However, steroid management is not uniformly efficacious in all patients receiving mTOR inhibitors. Furthermore, technology does not presently exist to permit clinicians to predict a priori which of their patients will develop these lesions. There thus remains a strategic need to define the pathobiology of mIAS, the molecular basis of pain, and risk prediction relative to development of the clinical lesion. This knowledge could lead to novel future interventions designed to more effectively prevent mIAS and improve pain management if clinically significant mIAS lesions develop.

show abstract

“…In this study, low BMI was one of the risk factors in the validation group, but it was not confirmed as a risk factor in the experimental group. Clinical practice guidelines have been drawn for the management of OM based on evidence and expert opinions (28)(29)(30). Oral care reduces the microbial load; therefore, maintenance of oral hygiene is a major factor in the prevention and mitigation of oral injury.…”

Section: Discussionmentioning

confidence: 99%

Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer

Sakamoto

Takeda

Kanekiyo

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up

Cited by 204 publications

References 40 publications

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice

Association of tumor necrosis factor-α polymorphism with chemotherapy-induced oral mucositis in patients with esophageal cancer

Contact Info

Product

Resources

About